ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  

Found 88 studies with search of:   "Niacin"

Hide studies that are not seeking new volunteers.
Show Display Options  Display Options

1 Active, not recruiting A Placebo-Controlled Prospective Study to Evaluate Flushing in Subjects Administered Niaspan® Plus Aspirin for Six Weeks
Condition: Dyslipidemia
Interventions: Drug: Niaspan plus aspirin;   Drug: Niaspan plus aspirin placebo;   Drug: Niaspan placebo/aspirin placebo
2 Completed Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)(COMPLETED)
Conditions: Hypercholesterolemia;   Hyperlipidemia
Interventions: Drug: Vytorin + Niaspan;   Drug: Vytorin;   Drug: Niaspan
3 Recruiting Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)
Condition: Elevated Lipoprotein(a) Levels
Interventions: Drug: Nicotinic acid (niacin);   Drug: Placebo
4 Recruiting Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Condition: Opioid Abuse
Interventions: Drug: Niacin;   Drug: Oxycodone HCL plus Niacin;   Drug: Placebo;   Drug: Oxycodone HCL plus Niacin;   Drug: Oxycodone HCl
5 Completed A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites
Conditions: Dyslipidemia;   Type 2 Diabetes Mellitus
Interventions: Drug: niacin (+) laropiprant;   Drug: laropiprant;   Drug: Comparator: niacin;   Drug: Comparator: placebo (unspecified)
6 Active, not recruiting Niacin, N-3 Fatty Acids and Insulin Resistance
Conditions: Metabolic Syndrome;   Hypertriglyceridemia
Interventions: Drug: omega-3 acid ethyl esters;   Drug: extended release niacin;   Drug: placebo;   Drug: omega-3 acid ethyl esters;   Drug: combined treatment
7 Completed SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia
Condition: Dyslipidemia
Intervention: Drug: Slo-Niacin, atorvastatin
8 Completed To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With High Cholesterol
Condition: Hypercholesterolemia
Interventions: Drug: ezetimibe (+) simvastatin;   Drug: niacin (ER) tablet;   Drug: ezetimibe/simvastatin + niacin (ER);   Drug: Placebo (unspecified)
9 Active, not recruiting Extended Niacin/Laropiprant in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus Type 2
Interventions: Drug: ER niacin/laropiprant;   Drug: Comparator : placebo (unspecified)
10 Recruiting Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function
Conditions: Coronary Disease;   Hypolipoproteinemia
Interventions: Behavioral: physical exercise;   Drug: niaspan (extended-release niacin);   Drug: niacin;   Other: control
11 Recruiting Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Condition: Peripheral Arterial Disease
Interventions: Drug: Ezetimibe;   Drug: Niaspan;   Drug: Statin therapy;   Behavioral: Standard care;   Drug: Aspirin;   Drug: Clopidogrel;   Drug: Placebo Niaspan;   Drug: Placebo Ezetimibe;   Procedure: Percutaneous transluminal angioplasty (PTA)
12 Recruiting Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia
Condition: Dyslipidemia
Interventions: Drug: ABT-919;   Drug: ASA;   Drug: niacin placebo;   Drug: ASA placebo
13 Recruiting Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)
Condition: Coronary Artery Disease
Interventions: Drug: Niacin;   Drug: Niacin+Statin
14 Completed Tolerability of MK0524A Versus Niacin Extended-Release
Conditions: Hypercholesterolemia;   Hyperlipidemia
Interventions: Drug: niacin (+) laropiprant;   Drug: niacin
15 Completed Effect of an Investigational Compound on Tolerability of Extended Release Niacin
Conditions: Hypercholesteremia;   Hyperlipidemia
Interventions: Drug: niacin (+) laropiprant;   Drug: Comparator : niacin
16 Recruiting Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
Conditions: Coronary Artery Disease;   Carotid Artery Diseases;   Atherosclerosis
Interventions: Drug: Atorvastatin;   Drug: Extended Release Niacin;   Drug: Colesevelam;   Drug: Placebo Niacin;   Drug: Placebo Colesevelam
17 Completed Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
Condition: Pain
Interventions: Drug: Oxycodone HCl/Niacin Tablets 5/30 mg;   Drug: Oxycodone HCl/Niacin 7.5/30 mg;   Drug: Placebo
18 Completed The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)
Condition: Metabolic Syndrome
Interventions: Drug: Extended-Release Niacin;   Drug: Placebo
19 Completed An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)
Conditions: Hyperlipidemia;   Mixed Dyslipidemia
Interventions: Drug: Niacin ER/Simvastatin Tablets;   Drug: atorvastatin
20 Completed Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
Condition: Hypercholesterolemia
Intervention: Drug: Niacin Extended-Release and simvastatin Tablets
21 Completed Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
Conditions: Metabolic Syndrome X;   Insulin Resistance
Interventions: Drug: fenofibrate;   Drug: niacin;   Drug: rosiglitazone
22 Recruiting A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
Conditions: Hyperlipidemia;   Hypercholesterolemia
Interventions: Drug: ezetimibe;   Drug: niacin;   Drug: colestipol
23 Recruiting Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
Conditions: Cardiovascular Diseases;   Heart Diseases;   HIV Infections;   Hyperlipidemia;   Hypertriglyceridemia;   Insulin Resistance;   Atherosclerosis
Interventions: Behavioral: Diet;   Behavioral: Exercise;   Drug: Niacin;   Drug: Fenofibrate;   Other: Placebos
24 Completed Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
Conditions: Hyperlipidemia;   Mixed Hyperlipidemia;   Dyslipidemia
Intervention: Drug: Niacin Extended Release/Lovastatin
25 Completed Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
Conditions: Intermittent Claudication;   Peripheral Vascular Disease
Intervention: Drug: Niacin Extended Release and Lovastatin Tablets
26 Completed Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
Condition: Hypercholesterolemia
Intervention: Drug: Niacin extended release and simvastatin tablets
27 Completed The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
Conditions: Intermittent Claudication;   Peripheral Vascular Disease
Intervention: Drug: Niacin Extended Release and Lovastatin Tablets
28 Completed Study of Extended Release Niacin/Laropiprant on Lipids
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Interventions: Drug: Comparator: simvastatin;   Drug: niacin (+) laropiprant;   Drug: Comparator: atorvastatin calcium
29 Withdrawn Extended Release (ER) Niacin/Laropiprant Add on Study
Condition: Dyslipidemia
Interventions: Drug: niacin (+) laropiprant;   Drug: placebo (unspecified)
30 Completed A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
Condition: Healthy
Intervention: Drug: GSK256073A tablets + IR niacin tablets
31 Completed Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
Conditions: HIV Infections;   Hypercholesterolemia;   Hypertriglyceridemia;   Diabetes Mellitus
Intervention: Drug: Niacin
32 Completed MK0524A Phase IIb Study
Condition: Flushing
Interventions: Drug: Comparator: niacin / Duration of Treatment: 17 Weeks;   Drug: MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks;   Drug: Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks
33 Recruiting Niacin Plus Statin to Prevent Vascular Events
Conditions: Cardiovascular Diseases;   Heart Diseases;   Cerebrovascular Accident;   Coronary Disease;   Atherosclerosis;   Myocardial Infarction
Interventions: Drug: Niacin;   Drug: Statin
34 Recruiting To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
Condition: Retinal Vein Occlusion
Intervention: Drug: Niacin
35 Recruiting Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions
Conditions: Central Retinal Vein Occlusion;   Branch Retinal Vein Occlusion
Intervention: Drug: Niacin
36 Recruiting Niacin to Improve Blood Flow in People With Sickle Cell Disease
Condition: Sickle Cell Disease
Interventions: Drug: Niacin-ER;   Drug: Placebo
37 Completed Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
Conditions: Dyslipidemia;   Coronary Heart Disease;   Atherosclerosis;   Stroke;   Diabetes
Interventions: Drug: Niacin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Ezetimibe;   Drug: Rosuvastatin
38 Recruiting Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis
Condition: Atherosclerosis
Interventions: Drug: extended release niacin;   Drug: ezetimibe
39 Completed Effect of MK0524A on Flushing Caused by Niacin
Condition: Flushing
Interventions: Drug: MK0524A, /Duration of Treatment : 4 Weeks;   Drug: Comparator : niacin /Duration of Treatment : 1 Weeks
40 Recruiting Pioglitazone Vs Placebo in Combination With Niacin Extended Release on Low HDL
Condition: Metabolic Syndrome
Intervention: Drug: Pioglitazone +/- placebo in combination with niacin ER
41 Not yet recruiting Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression
Condition: Healthy
Intervention: Drug: nicotinic acid
42 Active, not recruiting Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function
Condition: Atherosclerosis
Intervention: Drug: Niaspan
43 Completed Lipid Efficacy/Tolerability Study
Conditions: Primary Hypercholesterolaemia;   Mixed Hyperlipidaemia
Interventions: Drug: niacin (+) laropiprant;   Drug: ER-niacin
44 Recruiting Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
Conditions: Cardiovascular Disease;   Peripheral Arterial Disease;   Diabetes Mellitus;   Coronary Heart Disease
Interventions: Drug: ER niacin/laropiprant;   Drug: simvastatin;   Drug: ezetimibe
45 Completed High-Density Lipoprotein (HDL) Treatment Study
Conditions: Coronary Arteriosclerosis;   Hypoalphalipoproteinemias;   Genetic Diseases, Inborn
Intervention: Drug: Atorvastatin; Fenofibrate; Niacin
46 Recruiting Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) -A RCT
Conditions: Dyslipidemia;   Atherosclerosis
Intervention: Drug: nicotinic acid in addition to simvastatin
47 Completed MK0524A Clinical Efficacy Study
Condition: Hypercholesterolemia
Interventions: Drug: Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks;   Drug: MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks;   Drug: Comparator : niacin / Duraton of Treatment: 4 Weeks
48 Recruiting Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers
Conditions: Healthy, no Evidence of Disease;   Non-Melanomatous Skin Cancer
Interventions: Drug: placebo;   Drug: topical myristyl nicotinate cream
49 Recruiting Obesity and Nonalcoholic Fatty Liver Disease
Condition: Non-Alcoholic Fatty Liver Disease
Intervention: Drug: niacin, fenofibrate, pioglitazone
50 Completed Lipid Efficacy Study
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: niacin (+) laropiprant (+) simvastatin;   Drug: Comparator: niacin (+) laropiprant;   Drug: Comparator: simvastatin

Studies Shown (1-50) Next (51-88) Show next page of results

RSS Feed for studies found by your search that were received in the last 14 days  RSS Feed for studies found by your search that were received in the last 14 days  

Show download Options  Download Options

U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act
U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services



Links to all studies - primarily for crawlers